Kooperativer Bibliotheksverbund

In: European Heart Journal - Cardiovascular Imaging, Oxford University Press (OUP), Vol. 15, No. 6 ( 2014-06-01), p. 651-658

Type of Medium: Online Resource

ISSN: 2047-2404 , 2047-2412

URL: Article

DOI: 10.1093/ehjci/jet263

Language: English

Publisher: Oxford University Press (OUP)

Publication Date: 2014

detail.hit.zdb_id: 2042482-6

detail.hit.zdb_id: 2647943-6

In: European Heart Journal - Cardiovascular Imaging, Oxford University Press (OUP), Vol. 15, No. 3 ( 2014-03-01), p. 235-248

Type of Medium: Online Resource

ISSN: 2047-2404 , 2047-2412

URL: Article

DOI: 10.1093/ehjci/jet138

Language: English

Publisher: Oxford University Press (OUP)

Publication Date: 2014

detail.hit.zdb_id: 2042482-6

detail.hit.zdb_id: 2647943-6

In: Der Anaesthesist, Springer Science and Business Media LLC, Vol. 70, No. 9 ( 2021-09), p. 772-784

Type of Medium: Online Resource

ISSN: 0003-2417 , 1432-055X

URL: Article

DOI: 10.1007/s00101-021-00934-7

Language: German

Publisher: Springer Science and Business Media LLC

Publication Date: 2021

detail.hit.zdb_id: 3122926-8

detail.hit.zdb_id: 1458421-9

In: Journal of Clinical Monitoring and Computing, Springer Science and Business Media LLC, Vol. 35, No. 2 ( 2021-04), p. 229-243

Abstract: The number of high-risk patients undergoing surgery is growing. To maintain adequate hemodynamic functioning as well as oxygen delivery to the vital organs (DO 2 ) amongst this patient population, a rapid assessment of cardiac functioning is essential for the anesthesiologist. Pinpointing any underlying cardiovascular pathophysiology can be decisive to guide interventions in the intraoperative setting. Various techniques are available to monitor the hemodynamic status of the patient, however due to intrinsic limitations, many of these methods may not be able to directly identify the underlying cause of cardiovascular impairment. Hemodynamic focused echocardiography, as a rapid diagnostic method, offers an excellent opportunity to examine signs of filling impairment, cardiac preload, myocardial contractility and the function of the heart valves. We thus propose a 6-step-echocardiographic approach to assess high-risk patients in order to improve and maintain perioperative DO 2 . The summary of all echocardiographic based findings allows a differentiated assessment of the patient's cardiovascular function and can thus help guide a (patho)physiological-orientated and individualized hemodynamic therapy.

Type of Medium: Online Resource

ISSN: 1387-1307 , 1573-2614

URL: Article

DOI: 10.1007/s10877-020-00534-7

Language: English

Publisher: Springer Science and Business Media LLC

Publication Date: 2021

detail.hit.zdb_id: 2010139-9

In: Journal of Orthopaedic Surgery and Research, Springer Science and Business Media LLC, Vol. 18, No. 1 ( 2023-04-06)

Abstract: To implement a goal-directed fluid therapy (GDFT) protocol using crystalloids in hip revision arthroplasty surgery within a quality management project at a tertiary hospital using a monocentric, prospective observational study. Methods Adult patients scheduled for elective hip revision arthroplasty surgery were screened for inclusion in this prospective study. Intraoperatively stroke volume (SV) was optimized within a previously published protocol using uncalibrated pulse contour analysis and balanced crystalloids. Quality of perioperative GDFT was assessed by protocol adherence, SV increase as well as the rate of perioperative complications. Findings were then compared to two different historical groups of a former trial: one receiving GDFT with colloids (prospective colloid group) and one standard fluid therapy (retrospective control group) throughout surgery. Statistical analysis constitutes exploratory data analyses and results are expressed as median with 25th and 75th percentiles, absolute and relative frequencies, and complication rates are further given with 95% confidence intervals for proportions using the normal approximation without continuity correction. Results Sixty-six patients underwent GDFT using balanced crystalloids and were compared to 130 patients with GDFT using balanced colloids and 130 controls without GDFT fluid resuscitation. There was a comparable increase in SV (crystalloids: 65 (54–74 ml; colloids: 67.5 (60–75.25 ml) and total volume infused (crystalloids: 2575 (2000–4210) ml; colloids: 2435 (1760–3480) ml; and controls: 2210 (1658–3000) ml). Overall perioperative complications rates were similar (42.4% (95%CI 30.3–55.2%) for crystalloids and 49.2% (95%CI 40.4–58.1%) for colloids and lower compared to controls: 66.9% (95%CI 58.1–74.9)). Interestingly, a reduced number of hemorrhagic complications was observed within crystalloids: 30% (95%CI 19.6–42.9); colloids: 43% (95%CI 34.4–52.0); and controls: 62% (95%CI 52.6–69.9). There were no differences in the rate of admission to the post-anesthesia care unit or intensive care unit as well as the length of stay. Conclusions Perioperative fluid management using a GDFT protocol with crystalloids in hip revision arthroplasty surgery was successfully implemented in daily clinical routine. Perioperative complications rates were reduced compared to a previous management without GDFT and comparable when using colloids. Trial registration : ClinicalTrials.gov identifier: NCT01753050.

Type of Medium: Online Resource

ISSN: 1749-799X

URL: Article

DOI: 10.1186/s13018-023-03738-0

Language: English

Publisher: Springer Science and Business Media LLC

Publication Date: 2023

detail.hit.zdb_id: 2252548-8

In: Pediatric Rheumatology, Springer Science and Business Media LLC, Vol. 15, No. S1 ( 2017-5)

Type of Medium: Online Resource

ISSN: 1546-0096

URL: Article

DOI: 10.1186/s12969-017-0141-9

Language: English

Publisher: Springer Science and Business Media LLC

Publication Date: 2017

detail.hit.zdb_id: 2279468-2

In: Annals of the Rheumatic Diseases, BMJ, Vol. 81, No. Suppl 1 ( 2022-06), p. 142-143

Abstract: Tocilizumab (TCZ) has been approved for treatment of juvenile idiopathic arthritis (JIA) for 10 years. Objectives Evaluation of 12-month efficacy and safety of TCZ compared to TNF inhibitors (TNFi). Methods BIKER WA 29358 is a 5-year multi-centre prospective, observational cohort study including polyarticular JIA patients in Germany starting treatment between 2015 and 2020 with TCZ and matched 1:1 by date of treatment start and region to patients starting an approved TNFi. Clinical disease activity (JADAS10), JADAS MDA (≦3.8)/remission (≦1.0), safety and drug adherence at 12 months were assessed and compared between cohorts. Results The analysis included 342 participants with 12-month treatment data (TCZ n=171; TNFi n=171). TCZ was used as 2nd line biologic in the majority of patients (84%) while TNFi were mostly 1st line biologics (86%). Patients starting TCZ had a longer disease duration. Efficacy was demonstrated by a marked decrease in JADAS10 in both cohorts (TCZ vs. TNFi at baseline: 15.0+/-6.7 vs. 14.6+/-6.3; at month 12: 3.8+/-5.1 vs. 3.4+/-4.5). Proportions of patients in TCZ/TNFi cohorts achieving JADAS remission at 12 months were 48%/41% in 1st line biologic users and 32%/33% in 2nd line biologic users. JADAS MDA was achieved in 64%/69% in 1st line and 52%/58% in 2nd line users of TCZ/TNFi. After 12 months of treatment JADAS10 (mean +/SD) was higher in the 2nd line TNFi cohort compared to the 1st line (4.5+/-5.6 vs. 3.2+/-4.3), similar to patients receiving 2nd or 1st line TCZ (4.0+/-5.2 vs. 2.9+/-4.4). Patients receiving TCZ or TNFi as first biologic reached JADAS10 remission and MDA numerically more frequently but not statistically significant compared to 2nd line users. Safety was assessed based on adverse event (AE) reporting. 57 (33%) patients in the TCZ cohort and 43 (25%) patients in the TNFi cohort reported AE. The AE rate was significantly higher in the TCZ cohort (69 vs. 44.8/100 patient years, RR 1.5 [95%CI 1.1-2.0], p=0.006, Wald-test). There were 6 serious AE in the TCZ and 3 in the TNFi cohort. Injection site reactions were more common in the TNFi cohort (9 vs. 1, p=0.043). No further differences were identified to date. There was no death and no opportunistic infection. In the TCZ cohort, 32 patients discontinued treatment, 27 due to lack of efficacy, while in the TNFi cohort only 6 patients discontinued treatment. Treatment discontinuation was more frequent among the 2nd biologic users (n=29; 17.4%) than in first line users (n= 9; 5.1%). Conclusion In this first interim analysis, treatment targets were reached with similar frequency after 12 months of treatment with TCZ or TNFi. TCZ was used predominantly as 2nd line biologic. Higher rates of remission /MDA were observed in 1st line compared to 2nd line biologic users. Although more AE were reported in the TCZ cohort, the occurrence of serious AE and infections was comparable in both cohorts. No new safety signals were identified. Observation is ongoing. Table 1. Baseline characteristics and discontinuations with reasons. Number, n TNFi 1 st 147 TNFi 2 nd 24 TNFi total 171 TCZ 1 st 27 TCZ 2 nd 144 TCZ total 171 Female, % 119(81%) 20 (83%) 139(81%) 20(74%) 123(85%) 143(84%) Disease duration, years 2.7+/-2.7 6.5+/-3.3 3.2+/-3.1 2.5+/-2.7 5.9+/-4.1 5.4+/-4.1 Pre-treatment n.a. None=147 (86%) n.a. None=27 (16%) 1 biologic 14 (58%) 14 (8%) 80 (56%) 80 (47%) 2 biologics 7 (29%) 7 (4%) 54 (38%) 54 (32%) ≥ 3 biologics 3 (13%) 3 (2%) 10 (7%) 10 (6%) CHAQ-DI, mean +/- SD 0.67+/-0.64 0.31+/-0.45 0.63+/-0,63 0.43+/-0.44 0.65+/-0.65 0.61+/-0.62 JADAS 10, mean +/- SD 14.8+/-6.3 13.4+/-6.8 14.6+/-6.3 13.3+/-6.0 15.3+/-7.0 15.0+/-6.7 Concomitant MTX, n (%) 120 (82%) 13 (54%) 133 (78%) 17 (63%) 75 (52%) 92 (54%) Steroid, n (%) 37 (25%) 4 (17%) 41 (24%) 8 (30%) 35 (24%) 43 (25%) Discontinuations, n (%) 5 (3.4%) 1 (4.2%) 6 (3.5%) 4 (16%) 28 (19%) 32 (19%) -Inefficacy 1 (0.7%) 2 (1.2%) 3 (12%) 24 (17%) 27 (16%) -Intolerance 2 (1.4%) 1 (4.2%) 2 (1.2%) 2 (1.4%) 2 (1.2%) -Other 2 (1.4%) 2 (1.2%) 1 (4%) 4 (2.8%) 5 (3.0%) Disclosure of Interests Ariane Klein Speakers bureau: Novartis fee chairing a lunch symposium, Angela Zimmer: None declared, Toni Hospach: None declared, Frank Weller-Heinemann: None declared, Sandra Hansmann: None declared, Jasmin Kuemmerle-Deschner: None declared, Maria Fasshauer: None declared, Kirsten Minden Speakers bureau: Honoraries from Novartis, Pfizer, Medac, Ivan Foeldvari: None declared, Christoph Rietschel: None declared, Daniel Windschall Speakers bureau: Pfizer, Novartis, Abbvie, MEDAC, Canon, Grant/research support from: Novartis, Pfizer, Ralf Trauzeddel: None declared, Markus Hufnagel: None declared, Dirk Foell: None declared, Rainer Berendes: None declared, Gundula Boeschow: None declared, Prasad Oommen: None declared, Frank Dressler Speakers bureau: Honoraries from Novartis, Pfizer, Abbvie, Consultant of: Advisory board Novartis, Mylan, Gerd Horneff Speakers bureau: Novartis, Pfizer, Janssen, Grant/research support from: Pfizer, Novartis, Roche, MSD

Type of Medium: Online Resource

ISSN: 0003-4967 , 1468-2060

URL: Article

DOI: 10.1136/annrheumdis-2022-eular.1774

Language: English

Publisher: BMJ

Publication Date: 2022

detail.hit.zdb_id: 1481557-6

In: Annals of the Rheumatic Diseases, BMJ, Vol. 79, No. Suppl 1 ( 2020-06), p. 1201.2-1202

Abstract: Tocilizumab (TOC) is approved for treatment of polyarticular juvenile idiopathic arthritis (pJIA). Data out of clinical practice are limited. Objectives: Long-term surveillance of patients initiating TOC treatment compared to a cohort of patients initiating a comparator biologic using the BIKER-registry. Methods: Baseline parameters, efficacy and safety parameters were compared. Efficacy outcomes were JADAS10 and joint counts. Functional status was determined with the Childhood Health Assessment Questionnaire disability-index (CHAQ-DI). Safety was assessed by adverse events (AE) reports. Results: Until January 2020, 152 patients have been recruited to each cohort. Patients starting on TOC were older at treatment start (12.1 vs. 10.1 years (y); p 〈 0.0001) and had a longer disease duration (5.4y vs. 3.0y; p 〈 0.0001). TOC was significantly more often a second-line biologic (84% vs 13%, p 〈 0.0001). Otherwise patients were comparable (Table 1). Table 1. Comparison of TOC patients and matched controls. Tocilizumab N=152 Matched controls N=152 p Gender female, n (%) 128 (84) 124 (81) 0.65 Disease duration, mean (SD), years 5.4 (4.1) 3.0 (2.9) 〈 0.0001 RF neg. polyarthritis, n (%) 104 (68.4) 92 (60.5) 0.19 RF pos. polyarthritis, n (%) 14 (9.2) 19 (12.5) 0.46 Extended oligoarthritis, n (%) 34 (22.4) 41 (27) 0.42 Pretreatment with biologics, n(%) 127 (83.5) 20 (13.2) 〈 0.0001 Active joint count, mean (SD) 6.7 (7.1) 6.1 (5.1) 0.4 CHAQ DI, mean (SD) 0.63 (0.63) 0.65 (0.64) 0.8 ESR, mm/h, mean (SD) 17.5 (14.9) 20.9 (20.6) 0.1 JADAS10, mean (SD) 16.8 (9.8) 15.1 (5.8) 0.067 Efficacy Month 12 N=87 N=105 JADAS MDA, n (%) 50 (57.5) 63 (60.0) 0.77 JADAS REM, n (%) 32 (36.8) 39 (37.1) 1.0 JIA ACR 30/50/70/90, % 80/75/61/53 86/84/70/56 0.34/0.15/0.17/0.66 Adverse events N (rate/100PY; 95%CI ) 248,65 PY 290.4 PY RR (95%CI); p AE 145 (58.3; 50-69) 157 (54.1; 46-63) 1.1 (0.9-1.4); 0.5 SAE 12 (4.8; 2.7-8.5) 4 (1.4; 0.5-3.7) 3.5 (1.1-10.9); 0.03 Medically important infection 2 (0.8; 0.2-3.2) 12 (4.1; 2.3-7.3) 0.2 (0.04-0.9); 0.03 Uveitis event 2 (0.8; 0.2-3.2) 12 (4.1; 2.3-7.3) 0.2 (0.04-0.9); 0.03 Upon TOC a substantial response to treatment with a significant reduction in JADAS 10 from 16.8 to 3.4 (p 〈 0.0001) after 12 months was observed. There were no significant differences between patients from the TOC cohort and their matched controls regarding JIA ACR 30/50/70/90 criteria and active joint counts. JADAS 10, JADAS remission (REM) and minimal disease activity (MDA) was reached by comparable numbers in the TOC (37% and 58%) and the control cohort (37% and 60%). While the total number of AE was comparable between the TOC cohort (58/100PY) and in the control cohort (54/100PY; RR 1.1; 95%CI 0.9-1.4), more serious AE (SAE) were reported with TOC (4.8/100PY compared to 1.4/100PY; RR 3.5; 95% CI 1-10.9). Medically important infections and uveitis events were documented at significantly lower frequency in the TOC- (0.8/100PY) than in the control cohort (4.1/100PY; RR 0.2; 95% CI 0.04-0.9). SAE with TOC were suicidal intent (n=3), depression (n=2), exacerbation of JIA, abscess, gastrointestinal infection, abdominal pain, colitis, bone surgery and fracture (n=1). SAE in the control cohort were depression, osteomyelitis, gastrointestinal infection and superinfected eczema (n=1). No significant differences regarding cytopenia and elevated transaminases were observed. No gastrointestinal perforation, no vascular event, no malignancy and no death occurred. Conclusion: The efficacy of tocilizumab is comparable to that of alternative biologics. Tolerability was acceptable. As Tocilizumab was given as a second-line biologic in the vast majority of patients, comparisons between the cohorts have to be interpreted carefully. Observation in the registry is ongoing. Disclosure of Interests: Ariane Klein Consultant of: Celgene, Toni Hospach: None declared, Frank Weller-Heinemann: None declared, Sandra Hansmann Consultant of: Advisory board Novartis Pharma, Jasmin Kuemmerle-Deschner Grant/research support from: Novartis, Sobi, Consultant of: Novartis, Sobi, Speakers bureau: Novartis, Sobi, Maria Fasshauer Consultant of: Shire, CSL Behring, Kirsten Minden Consultant of: GlaxoSmithKline, Sanofi, Speakers bureau: Roche, Ivan Foeldvari Consultant of: Novartis, Christoph Rietschel Consultant of: Pfizer, Abbvie, Novartis, Chugai, and Sobi, Tobias Schwarz: None declared, Ralf Trauzeddel: None declared, Markus Hufnagel: None declared, Dirk Foell Grant/research support from: Novartis, Sobi, Pfizer, Speakers bureau: Novartis, Sobi, Rainer Berendes: None declared, Gundula Boeschow: None declared, Prasad Oommen Consultant of: Novartis, Frank Dressler: None declared, Astrid Helling-Bakki: None declared, Gerd Horneff Grant/research support from: AbbVie, Chugai, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Speakers bureau: AbbVie, Bayer, Chugai, Merck Sharp & Dohme, Novartis, Pfizer, Roche

Type of Medium: Online Resource

ISSN: 0003-4967 , 1468-2060

URL: Article

DOI: 10.1136/annrheumdis-2020-eular.4363

Language: English

Publisher: BMJ

Publication Date: 2020

detail.hit.zdb_id: 1481557-6

In: Pediatric Rheumatology, Springer Science and Business Media LLC, Vol. 9, No. S1 ( 2011-12)

Type of Medium: Online Resource

ISSN: 1546-0096

URL: Article

DOI: 10.1186/1546-0096-9-S1-P193

Language: English

Publisher: Springer Science and Business Media LLC

Publication Date: 2011

detail.hit.zdb_id: 2279468-2

In: Annals of the Rheumatic Diseases, BMJ, Vol. 81, No. Suppl 1 ( 2022-06), p. 315.2-315

Abstract: The ProKind Commission of the Society for Paediatric and Adolescent Rheumatology (GKJR) has developed evidence- and consensus-based protocols for the diagnosis and therapy of children and adolescents with defined rheumatic diseases (e.g., [1]). In the ProKind-Rheuma project, it is now investigated whether the protocols are followed in everyday clinical practice and what the treatment-associated outcomes are. Objectives To investigate the mode of treatment and treatment response in patients with polyarticular juvenile idiopathic arthritis (pJIA). Methods ProKind-Rheuma is a multicenter prospective non-interventional observational study. Patients with pJIA enrolled until 17/1/2022 were included into this analysis. Treatments and outcomes up to the 3-month follow-up visit (3FU) were analyzed. Disease states were categorized based on the 2021 cJADAS10 cutoffs [2]. Results To date, 18 pediatric rheumatology facilities have participated in ProKind-Rheuma. Data from 203 patients with JIA are available. Of those, 44% have oligoarthritis, 36% polyarthritis, 9% systemic JIA, 6% enthesitis-related arthritis and 3% psoriatic arthritis. In total, 76 patients were diagnosed with pJIA, 38 with already completed 3FU: For 23 patients with pJIA and completed 3FU, we were able to analyze the protocol-defined [1] treatment goal of at least “minimal im provement”. In total, 18 (78%) achieved minimal improvement, 5 (22%) missed it. For 4 of those 5 patients, the underlying MTX therapy was escalated to a bDMARD (3 changed to MTX+bDMARD-combi, 1 to bDMARD-mono). In 3 other patients, therapy was also escalated to an MTX+bDMARD-combi. Between baseline and 3FU, 72% achieved cJADAS10-disease state improvement (Table 1) by at least one category (range 1 - 2), 0% decreased. Table 1. *based on non-missing values At Baseline all At Baseline with 3FU At 3FU Total 76 38 Female, n (%) 58 (76) 30 (79) Age (years), Mdn (IQR) 9 (3-12) 7 (2-12) 7.5 (3-12) Time since diagnosis (months), Mdn (IQR) 0 (0-1) 0 (0-1) 4 (3-4) RF-positivity, n (%) 8 (11) 3 (8) Number of active joints (arthritis), Mdn (IQR) 7 (4-12) 7 (5-12) 2 (0-4) JADAS10 (0-40), Mean (SD) (N BL+3FU = 23) 18.6 (7.4) 19.6 (7.6) 7.2 (4.2) cJADAS10 (0-30), Mean (SD) (N BL+3FU = 29) 16.3 (5.9) 16.7 (6.1) 7.1 (4.1) State of inactive disease (cJADAS10≤2.5), n (%*) 0 (0) 0 (0) 4 (13) State of minimal disease activity (2.5 〈 cJADAS10≤5), n (%*) 1 (2) 1 (3) 9 (28) State of moderate disease activity (5 〈 cJADAS10 ≤16), n (%*) 33 (54) 17 (50) 18 (56) State of high disease activity (cJADAS10 〉 16), n (%*) 27 (44) 16 (47) 1 (3) CHAQ (0-3), Mean (SD) 0.8 (0.8) 0.9 (0.8) 0.3 (0.5) Pain (NRS 0 - 10), Mean (SD) 4.3 (3) 4.7 (3) 2.2 (2.7) PedsQL 4.0 total score, Mean (SD) 66.3 (22.2) 65.4 (21.8) 78.4 (17.6) Intraarticular glucocorticoids 〉 4 joints (ever), n (%) 12 (16) 5 (13) 7 (18) Glucocorticoid pulses (ever), n (%) 22 (29) 12 (32) 13 (34) Methotrexate, n (%) 56 (74) 31 (82) 34 (90) bDMARDs, n (%) 7 (9) 2 (5) 9 (24) Within the first 3 months after diagnosis, the treatment pathways proposed by the ProKind Commission [1] were followed in about three-quarters of patients: i) 5 (13%) received MTX and intra-articular glucocorticoid injections in more than 4 joints (IAGC), but no high-dose intravenous glucocorticoid pulse (HDGC) or bDMARD; ii) 8 (21%) received MTX and HDGC (no bDMARD, no IAGC); iii) 16 (42%) patients received MTX, of whom 4 received a bDMARD up to or at the 3FU (no HDGC, no IAGC). Nine (24%) patients were not treated with MTX or did not fit any of these categories, mostly due to starting bDMARD therapy in conjunction with HDGC or IAGC. Conclusion In the routine care of JIA patients with polyarthritis, the proposed treatment protocol and treat-to-target strategy are followed in most patients. At 3FU, improvements of JADAS10 and other outcomes were evident, with 41% having achieved inactive or minimal active disease. ProKind is funded by the Innovation Fund “Gemeinsamer Bundesausschuss”, FKZ: 01VSF18031 References [1]Horneff et al. Pediatric Rheumatology 2017; 15:78 [2]Trincianti et al. Arthritis Rheumatol. 2021 Nov; 73(11):1966-1975 Acknowledgements We are grateful to all physicians, medical professionals and everyone else who has so far contributed and supported the ProKind-Rheuma project. Moreover, we want to express special gratitude to all patients and their parents for their participation. Disclosure of Interests Sascha Eulert: None declared, Kristina Vollbach: None declared, Klaus Tenbrock: None declared, Jens Klotsche: None declared, Dirk Foell Speakers bureau: Speaker fees/honoraria from Boehringer, Novartis, Werfen and Sobi, Grant/research support from: Novartis and Sobi, Johannes-Peter Haas: None declared, Frank Weller-Heinemann: None declared, Sonja Mrusek: None declared, Prasad Oommen: None declared, Daniel Windschall Speakers bureau: Research support and speakers fee: Pfizer, Novartis, Abbvie, Medac, Sobi, Canon, Grant/research support from: Research support and speakers fee: Pfizer, Novartis, Abbvie, Medac, Sobi, Canon, Kirsten Moenkemoeller: None declared, Tilmann Kallinich: None declared, Markus Hufnagel: None declared, Ivan Foeldvari Consultant of: Addvisory board: Hexal, Novartis, Pfizer, Toni Hospach Consultant of: Advisory board: Sobi, Novartis, Moritz Klaas: None declared, Michael Rühlmann: None declared, Ralf Trauzeddel: None declared, Normi Brueck: None declared, Catharina Schütz: None declared, J. B. Kuemmerle-Deschner: None declared, Ariane Klein: None declared, Kirsten Minden Speakers bureau: Speaker: Pfizer, Novartis, Gerd Horneff: None declared

Type of Medium: Online Resource

ISSN: 0003-4967 , 1468-2060

URL: Article

DOI: 10.1136/annrheumdis-2022-eular.2008

Language: English

Publisher: BMJ

Publication Date: 2022

detail.hit.zdb_id: 1481557-6